Literature DB >> 2267677

Drug combinations and the bioavailability of rifampicin.

W Fox1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2267677     DOI: 10.1016/0041-3879(90)90035-7

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


× No keyword cloud information.
  9 in total

1.  Bioavailability of rifampin in experimental murine tuberculosis.

Authors:  J Dickinson; A Guy; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Current trends in the management of tuberculosis.

Authors:  J M Grange; J L Stanford
Journal:  J R Soc Med       Date:  1994-12       Impact factor: 5.344

4.  Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.

Authors:  Marc Weiner; Charles Peloquin; William Burman; Chi-Cheng Luo; Melissa Engle; Thomas J Prihoda; William R Mac Kenzie; Erin Bliven-Sizemore; John L Johnson; Andrew Vernon
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

Review 5.  Drug treatment of tuberculosis--1992.

Authors:  P T Davidson; H Q Le
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 6.  Clinically significant drug interactions with antituberculosis agents.

Authors:  J M Grange; P A Winstanley; P D Davies
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

Review 7.  Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.

Authors:  Bjørn Blomberg; Bernard Fourie
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

9.  A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.

Authors:  Alessandro Schipani; Henry Pertinez; Rachel Mlota; Elizabeth Molyneux; Nuria Lopez; Fraction K Dzinjalamala; Joep J van Oosterhout; Steve A Ward; Saye Khoo; Gerry Davies
Journal:  Br J Clin Pharmacol       Date:  2016-01-30       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.